TECH Bio-Techne
company
SEC Filings & Insider Trading Activity 2026

CIK: 842023
Health Care
Biological Products, (No Diagnostic Substances) 82 filings
S&P 500

Latest Bio-Techne (TECH) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on August 22, 2025, a 10-Q quarterly report filed on February 4, 2026, an 8-K current report filed on February 11, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Bio-Techne (TECH) (SEC CIK 842023), with AI-powered section-by-section summaries updated daily.

10-Q: 60
10-K: 20
8-K: 2

Latest 2026 SEC Filing Dates

10-K Annual Report
Aug 22, 2025
10-Q Quarterly Report
Feb 4, 2026
8-K Current Report
Feb 11, 2026

AI 10-K Annual Report Analysis
Latest 10-K (2025-06-30)

Business Overview

  • Core business model: Life sciences reagents, instruments, and services for research and clinical diagnostics
  • No new products, services, or segments introduced or emphasized this year according to filing text
+3 more insights

Risk Factors

  • Cybersecurity risk due to potential breaches despite industry-standard defenses, reliance on third-party software and service providers increasing vulnerability
  • Cyber insurance coverage may be insufficient to cover claims arising from security breaches or cyberattacks
+1 more insights

Management Discussion & Analysis

  • Revenue $1.22B in FY2025, up 5% YoY; Protein Sciences sales $870.2M (+5%), Diagnostics and Spatial Biology $346.3M (+6%)
  • Gross margin declined to 64.8% in FY2025 vs 66.4% in FY2024; Protein Sciences margin 75.6% vs 75.7%, Diagnostics 57.3% vs 58.7%
+4 more insights

AI 10-Q Quarterly Report Analysis
Latest 10-Q (2025-12-31)

Risk Factors

  • Continued supply chain disruptions risk impacting production schedules carried from 10-K
  • Dependence on third-party suppliers with potential for raw material shortages carried from 10-K

Management Discussion & Analysis

  • Revenue $295.9M flat YoY for Q2 FY25; six months $582.4M, down 1% YoY; organic revenue flat in quarter, slight FX and held-for-sale impacts
  • Operating margin Protein Sciences 39.3% vs 41.2% YoY Q2; Diagnostics 10.4% vs 3.9% YoY Q2, drove margin improvement overall
Read full Q4 2025 10-Q analysis →

Annual Reports Archive
10-K

AI-powered analysis of Bio-Techne (TECH) 10-K annual reports filed with SEC EDGAR.

Quarterly Reports Archive
10-Q

AI-powered analysis of Bio-Techne (TECH) 10-Q quarterly reports filed with SEC EDGAR.

Financial Summary
XBRL

FY2022FY2023FY2024FY2025
Profitability
Revenue$1.1B$1.1B$1.2B$1.2B
Gross Profit$756.5M$769.8M$769.7M$790.3M
Operating Income$298.9M$206.7M$102.3M
Net Income$285.3M$168.1M$73.4M
Gross Margin68.4%67.7%66.4%64.8%
Op. Margin26.3%17.8%8.4%
Net Margin25.1%14.5%6.0%
Balance Sheet
Total Assets$2.6B$2.7B$2.6B
Equity$2.0B$2.1B$1.9B
ROE14.5%8.1%3.8%

Source: XBRL financial data from Bio-Techne (TECH) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.

Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4

FormFiling DatePeriodAnalysisSEC
8-K
Feb 11, 2026
8-K
Feb 4, 2026
10-Q
Feb 4, 2026Dec 31, 2025Analysis
10-Q
Nov 5, 2025Sep 30, 2025
10-K
Aug 22, 2025Jun 30, 2025Analysis
10-Q
May 8, 2025Mar 31, 2025
10-Q
Feb 6, 2025Dec 31, 2024
10-Q
Nov 5, 2024Sep 30, 2024
10-K
Aug 22, 2024Jun 30, 2024
10-Q
May 6, 2024Mar 31, 2024
10-Q
Feb 7, 2024Dec 31, 2023
10-Q
Nov 7, 2023Sep 30, 2023
10-K
Aug 23, 2023Jun 30, 2023
10-Q
May 8, 2023Mar 31, 2023
10-Q
Feb 7, 2023Dec 31, 2022
10-Q
Nov 7, 2022Sep 30, 2022
10-K
Aug 24, 2022Jun 30, 2022
10-Q
May 9, 2022Mar 31, 2022
10-Q
Feb 7, 2022Dec 31, 2021
10-Q
Nov 8, 2021Sep 30, 2021
10-K
Aug 25, 2021Jun 30, 2021
10-Q
May 7, 2021Mar 31, 2021
10-Q
Feb 8, 2021Dec 31, 2020
10-Q
Nov 9, 2020Sep 30, 2020
10-K
Aug 26, 2020Jun 30, 2020

Frequently Asked Questions

What are the latest TECH SEC filings in 2026?

Bio-Techne (TECH) has filed a 10-K annual report on August 22, 2025, a 10-Q quarterly report on February 4, 2026, an 8-K current report on February 11, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did TECH file its most recent 10-K annual report?

Bio-Techne (TECH) filed its most recent 10-K annual report on August 22, 2025. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view TECH 10-Q quarterly reports?

Bio-Techne (TECH)'s most recent 10-Q quarterly report was filed on February 4, 2026. SignalX displays every TECH 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has TECH filed recently?

Bio-Techne (TECH)'s most recent 8-K was filed on February 11, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find TECH insider trading activity (Form 4)?

SignalX aggregates every TECH Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does TECH file with the SEC?

Bio-Techne (TECH) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TECH filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Bio-Techne (TECH).

What is TECH's SEC CIK number?

Bio-Techne (TECH)'s SEC CIK (Central Index Key) number is 842023. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 842023 to look up all TECH filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find TECH return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Bio-Techne (TECH) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.

Stay on top of Bio-Techne SEC filings

Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 82+ filings.